Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Gilead’s suspension of Covid-19 trials in China should serve as bellwether for studies in other countries, says GlobalData

Following the news that China trials of Gilead Sciences Inc’s antiviral drug remdesivir in patients with mild symptoms of coronavirus (Covid-19) have been suspended due to lack of eligible patients; Michael Breen PhD, Associate Director of Infectious Diseases at GlobalData, a leading data and analytics company, provides his view:  “As the Covid-19 outbreak becomes controlled, […]
Read more

EU’s unity is being tested by COVID-19 outbreak, says GlobalData

The European Union needs more solidarity and coordinated actions to effectively respond to the COVID-19 outbreak, says GlobalData, a leading data and analytics company. Urte Jakimaviciute, MSc, Senior Director of Market Research at GlobalData, commented: “Even though the EU has been implementing various measures to mitigate the consequences of the COVID-19 outbreak, the bloc initially […]
Read more

COVID-19 and post-Brexit immigration system set to worsen NHS staffing crisis

Austerity measures, dissatisfaction with politics, lack of transparency in the EU’s decisions and uncontrolled immigration may have been the major factors influencing the Brexit vote. Nevertheless, constraints on post-Brexit immigration will hurt Britain’s labor market as a large proportion of UK businesses, including the UK’s National Health Service (NHS), rely on an external workforce. The […]
Read more

LabCorp’s at-home COVID-19 test to reduce demand for PPE

Following the Food and Drug Administration’s (FDA) authorization of the first COVID-19 diagnostic test with a home-collection option; Aliyah Farouk, Medical Device Analyst at GlobalData, a leading data and analytics company, offers her view: “GlobalData expects LabCorp’s at-home COVID-19 test to ease demand for much needed personal protective equipment (PPE). Although the test can currently […]
Read more

KidneyIntelX™ to assess risk of adverse kidney events in COVID-19 patients

Following the announcement that Renalytix AI’s KidneyIntelX™ platform will be used to assess the risk of kidney injury in COVID-19 patients; Azadeh Laffafian, Medical Device Analyst at GlobalData, a leading data and analytics company, offers her view: “There are multiple reports of acute kidney injury in hospitalized COVID-19 patients. Additionally, patients with prior kidney disease are […]
Read more

FDA special emergency program will accelerate COVID-19 therapies

As the COVID-19 pandemic spreads rapidly throughout the world, the urgency of finding a treatment has magnified. The Coronavirus Treatment Acceleration Program (CTAP), a special emergency program created by the Food and Drug Administration (FDA), will accelerate COVID-19 therapies by using all available methods to rapidly deliver new treatments to patients, says GlobalData, a leading […]
Read more

MSCs enter COVID-19 treatment race with best source and optimal dosing key unanswered questions

Several companies developing mesenchymal stromal cells (MSCs) for COVID-19 saw significant stock movement after announcing their plans, and early data is indeed encouraging for further exploration in clinical trials, according to reporting from Manasi Vaidya, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company. Yet, there are also several limitations with […]
Read more

Neurimmune and Ethris recovered patients antibody treatment for COVID-19 could remove plasma treatment bottleneck

As the COVID-19 pandemic continues to spread, collaborations between companies with differing areas of expertise could accelerate the availability of a treatment for the disease. Neurimmune and Ethris’ collaboration could produce a recovered patient antibody treatment that could be rapidly delivered to patients without requiring continued recovered patients’ plasma donations or continued verification of the antibodies […]
Read more

Recovered patient antibody treatments against COVID-19 underway

With the continuation of the COVID-19 pandemic and possible vaccines approximately one year away from launch, the race to find a treatment for the disease continues. A growing number of pharmaceutical companies have begun work on recovered patients’ antibody treatments for COVID-19. As monoclonal antibody (mAb) drugs are some of the top sellers in the […]
Read more

Stimulatory cell receptors key to three-drug combinations in future immuno-oncology treatments, says GlobalData

Emerging three-drug combinations are poised to redefine the immuno-oncology treatment paradigm in advanced malignancies with high unmet need, according to GlobalData, a leading data and analytics company. The oncology market is saturated with new drugs that target the immune system, however, these only target part of the problem caused by cancer’s ability to hide from […]
Read more

COVID-19 pandemic interferes with treatments in female health space

The American Society of Reproductive Medicine (ASRM) issued guidance on fertility treatments during COVID-19 and called for suspension of most new treatment cycles such as IVF. Furthermore, The European Society of Human Reproduction and Embryology (ESHRE) has advised women not to undergo IVF treatment during the pandemic. This may impact the demand and 2Q sales […]
Read more

BARDA supports Moderna’s COVID-19 vaccine candidate but many obstacles ahead to confirm potential of mRNA vaccine strategy

The Biomedical Advanced Research and Development Authority (BARDA) has agreed to provide up to $483m to assist Moderna in developing its COVID-19 vaccine candidate, but reporting from Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company, shows that experts are cautious about mRNA-1273’s potential to trigger sufficient immunogenicity. Castañeda says: “From […]
Read more
1 … 95 96 97 98 99 … 108